NCT01714908

Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21

A Multicenter, Randomized, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Erlotinib Versus Etoposide Plus Cisplatin With Concurrent Radiotherapy in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) With Activating Mutation of Epidermal Growth Factor Receptor (EGFR) in Exon 19 or 21

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Jinming Yu · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Erlotinib with concurrent radiotherapy has superior efficacy and comparable safety profile in unresectable stage III non-small cell lung cancer (NSCLC) patients with activating mutation of epidermal growth factor receptor (EGFR) in exon 19 or 21 versus etoposide plus cis-platin with concurrent radiotherapy.

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
OTHER	Erlotinib w Concurrent Radiotherapy
OTHER	etoposide/cis-platin (EP) w Concurrent Radiotherapy	Etoposide / Cis-platin w Concurrent Radiotherapy

Timeline

• Start date: 2012-12-14
• Primary completion: 2018-08-20
• Completion: 2018-10-20
• First posted: 2012-10-26
• Last updated: 2017-02-07

Locations

19 sites across 1 country: China